Details of the Drug Combination

General Information of Drug Combination (ID: DCVS3M3)

Drug Combination Name
PAC1 Ixazomib
Indication
Disease Entry Status REF
Glioblastoma Investigative [1]
Component Drugs PAC1   DMYQUIP Ixazomib   DM5ZVLB
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: JHH-136
Zero Interaction Potency (ZIP) Score: 57.231
Bliss Independence Score: 63.037
Loewe Additivity Score: 10.264
LHighest Single Agent (HSA) Score: 0.153

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of PAC1
Disease Entry ICD 11 Status REF
Anaplastic astrocytoma 2A00.0 Phase 1 [2]
Recurrent glioblastoma 2A00.00 Phase 1 [2]
PAC1 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Caspase-3 (CASP3) TTPF2QI CASP3_HUMAN Activator [4]
------------------------------------------------------------------------------------
Indication(s) of Ixazomib
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Approved [3]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2015
4 Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol. 2006 Oct;2(10):543-50.